Pharmaceutical News

RSS

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Teens and young adults face high risk from opioid-involved overdose

The prevalence of opioid-involved overdoses has become an increasing concern to health officials both in NYC and nationally.

3 Sep 2014

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder.

3 Sep 2014

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain.

3 Sep 2014

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

3 Sep 2014

Researchers create new drug to reduce inflammation of donor organ after transplantation

To reduce the number of discards and thus make more kidneys available, researchers and medical scientists from the European consortium MABSOT have created a new drug called OPN-305 to reduce inflammation of the donor organ after transplantation.

3 Sep 2014

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.

2 Sep 2014

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.

2 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI) is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 today.

2 Sep 2014

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.

2 Sep 2014

Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Permanent atrial fibrillation (AF) doubles the risk of stroke compared to paroxysmal AF, according to research in more than 6 000 patients presented at ESC Congress today by Dr Thomas Vanassche from Belgium. The findings suggest that a simple clinical assessment of the type of AF can help doctors to better estimate stroke risk.

2 Sep 2014

Serelaxin reduces occurrence of in-hospital worsening heart failure

Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. The results were presented for the first time today at ESC Congress by co-principal investigator Professor John R. Teerlink.

1 Sep 2014

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US.

1 Sep 2014

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule.

1 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA.

1 Sep 2014

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration.

1 Sep 2014

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

30 Aug 2014

Pharmaceutical News

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Teens and young adults face high risk from opioid-involved overdose

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Novel polypill increases patient adherence to treatment following heart attack

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Researchers create new drug to reduce inflammation of donor organ after transplantation

Amgen seeks EMA approval for marketing talimogene laherparepvec

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Ambulance administration of antiplatelet medication may help heart attack patients

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Serelaxin reduces occurrence of in-hospital worsening heart failure

New polypill increases adherence to treatment following myocardial infarction

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Darapladib drug fails to reduce risk of recurrent major coronary events

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News